Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Enoxaparin reduces Peripheral Neuropathy
Enoxaparin reduces Peripheral Neuropathy
Enoxaparin reduces Peripheral Neuropathy in myeloma patients undergoing Velcade therapy. Enoxaparin (brand name Lovenox) is a low-molecular-weight heparin (LMWH) primarily used as an anticoagulant (blood thinner).
Velcade-induced peripheral neuropathy is an excruciating side effect of MM patients undergoing bortezomib (Velcade). Statistics vary, but some studies cite as many as 75% of patients developing Velcade-induced peripheral neuropathy.
The video below gives a thorough explanation of Velcade, PN, dosing, etc.
Updated Version Available – All About Velcade (Bortezomib) for Myeloma
I am a long-term MM survivor. I have been fortunate to witness the occurrence of Velcade-induced PN reduced over the years with changes in administration, dosing, and now Enoxaparin given concurrently. Be sure to talk to your oncologist about this challenging side effect.
Email me at David.PeopleBeatingCancer@gmail.com to learn more about both conventional and non-conventional MM therapies.
Good luck,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Concomitant Use of Low Molecular Weight Heparin Mitigates Bortezomib-Induced Peripheral Neuropathy: Analysis of the FDA Adverse Event Reporting System
Highlights
- •Bortezomib combined with low molecular weight heparin significantly reduces peripheral neuropathy risk.
- •No significant interaction found with bortezomib and heparin in peripheral neuropathy cases.
- •Enoxaparin is a safer anticoagulant option for multiple myeloma patients.
- •Results suggest new therapeutic strategies for managing bortezomib-related peripheral neuropathy.
Abstract
The concurrent use of bortezomib and anticoagulants, including heparin and low molecular weight heparin (LMWH), is increasingly common in the standard clinical management of multiple myeloma.
Peripheral neuropathy (PN) is a common and significant toxicity associated with bortezomib. This study aimed to identify and characterize interaction signals for the concomitant use of bortezomib with heparin/LMWH, resulting in PN, using data mining of the FDA Adverse Event Reporting System (FAERS). Adverse event (AE) reports to FAERS were analyzed.
We conducted disproportionality analysis to detect PN signals associated with the combined use of bortezomib and heparin/LMWH by estimating reporting odds ratio (ROR) with 95% confidence interval (CI). Adjusted odds ratios (ORs) were calculated using logistic regression analysis (adjusting for age, sex, and reporting year), and the Ω shrinkage measure method was used to further confirm the findings.
Subset data analysis was performed based on the use of heparin and LMWH as a specific drug. From 84,428 AE reports, including 2,805 PN reports, the combined use of bortezomib and heparin/LMWH was associated with a lower PN reporting (OR = 1.852, 95% CI, 1.098-3.126) compared to bortezomib monotherapy (OR = 3.809, 95% CI, 3.435-4.224), indicating a significant interaction signal.
The results remained significant according to the Ω shrinkage measure method. In the subset analyses, an interaction signal was identified for enoxaparin but not for heparin. FAERS data suggest that combining bortezomib and LMWH, specifically enoxaparin, is associated with a reduced risk of PN reporting. No significant interaction was found between bortezomib and heparin…
Conclusions
Analysis of FAERS data indicates that the combination of bortezomib and LMWH (enoxaparin) is correlated with a reduced risk of reporting peripheral neuropathy in patients with MM. No significant interaction was detected between bortezomib and heparin, although a trend toward a reduction in PN incidence was observed. LMWH (enoxaparin) may represent a superior anticoagulant alternative better suited for bortezomib combination therapy in MM patients.
Enoxaparin reduces Peripheral Neuropathy Enoxaparin reduces Peripheral Neuropathy